{"doc_id": "si-2022-0417-reg-1", "parent_doc_id": "si-2022-0417", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 417 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "1. These Regulations may be cited as the European Communities (Clinical", "text_raw": "1. These Regulations may be cited as the European Communities (Clinical \nTrials on Medicinal Products For Human Use) (Amendment) Regulations", "text_norm": "1 regulation may cited european community (clinical trial medicinal product human use) (amendment) regulation", "start_char": 673, "end_char": 815, "source_path": "downloads\\2022\\2022_0416.pdf", "extraction_method": "pdfminer", "checksum": "sha256:3fb589c64e11faf5663ec09f19a158402de82e69872a1dc3fba31872e00a5d0a", "cross_refs": []}
{"doc_id": "si-2022-0417-reg-2022", "parent_doc_id": "si-2022-0417", "section_id": "reg-2022", "section_label": "Regulation 2022.", "si_number": "S.I. No. 417 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": null, "text_raw": "2022.", "text_norm": "2022", "start_char": 815, "end_char": 823, "source_path": "downloads\\2022\\2022_0416.pdf", "extraction_method": "pdfminer", "checksum": "sha256:3fb589c64e11faf5663ec09f19a158402de82e69872a1dc3fba31872e00a5d0a", "cross_refs": []}
{"doc_id": "si-2022-0417-reg-2", "parent_doc_id": "si-2022-0417", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 417 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "2. These Regulations shall be deemed to have come into operation on 1", "text_raw": "2. These Regulations shall be deemed to have come into operation on 1 \n\nJanuary 2022.", "text_norm": "2 regulation shall deemed come operation 1 january 2022", "start_char": 823, "end_char": 911, "source_path": "downloads\\2022\\2022_0416.pdf", "extraction_method": "pdfminer", "checksum": "sha256:3fb589c64e11faf5663ec09f19a158402de82e69872a1dc3fba31872e00a5d0a", "cross_refs": []}
{"doc_id": "si-2022-0417-reg-3", "parent_doc_id": "si-2022-0417", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 417 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "In these Regulations “Principal Regulations” means the European", "text_raw": "3. \n\nIn these Regulations “Principal Regulations” means the European \nCommunities (Clinical Trials on Medicinal Products For Human Use) \nRegulations 2004 (S.I. No. 190 of 2004).", "text_norm": "3 regulation principal regulation mean european community (clinical trial medicinal product human use) regulation 2004 (s.i no 190 2004)", "start_char": 911, "end_char": 1091, "source_path": "downloads\\2022\\2022_0416.pdf", "extraction_method": "pdfminer", "checksum": "sha256:3fb589c64e11faf5663ec09f19a158402de82e69872a1dc3fba31872e00a5d0a", "cross_refs": []}
{"doc_id": "si-2022-0417-reg-4", "parent_doc_id": "si-2022-0417", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 417 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "4. Regulation 4(1) is amended -", "text_raw": "4. Regulation 4(1) is amended - \n\n(a) by substituting for the definition of “Directive” the following: \n\n“‘Directive’ means Directive 2001/20/EC1 of the European \nParliament and of the Council of 4 April 2001 on the \napproximation of the laws, regulations and administrative \nprovisions of the Member States relating to the implementation \nof good clinical practice in the conduct of clinical trials on \nmedicinal products for human use (as amended);”, \n\n(b) by substituting for the definition of “Directive 2001/83/EC” the \n\nfollowing: \n“‘Directive 2001/83/EC’ means Directive 2001/83/EC of the \nEuropean Parliament and of the Council on the Community code \nrelating to medicinal products for human use3 (as amended);”, \n\n(c) by substituting for the definition of “export” the following: \n\n“‘export’ means export to a third country, other than Northern \nIreland, from the State, whether by land, sea or air;”, and \n\n(d) by substituting for the definition of “import” the following: \n\n“‘import’ means import to the State from a third country, other \nthan Northern Ireland, whether by land, sea or air;”. \n\n1 OJ No. L. 118, 20.4.2022, p.4. \n1 OJ No. L. 121, 01.05.2001, p.34. \n3 OJ No. L. 311, 28.11.2001, p.67. \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 23rd August, 2022. \n\n \n \n \n \n \n \n \n \n \n \n \n\f5. Regulation 11 of the Principal Regulations is hereby amended – \n(a) by substituting for subparagraph 2(c) the following: \n\n[417] 3 \n\n“(c) \n\nin the case of an investigational medicinal product – \n(i) \n\n(ii) \n\nimported from a third country, the product has been \nimported by a person holding a manufacturing \nauthorisation relating to the importation of that \nproduct, or \nimported from parts of the United Kingdom other \nthan Northern Ireland, until 31 December 2024, the \nBoard may allow product to be imported in the \nabsence of a manufacturing authorisation relating to \nthe importation of that product following receipt of a \nrequest from the sponsor provided that all of the \nfollowing conditions are fulfilled – \n(I) \n\ninto \n\ninvestigational medicinal \n\nproducts \nthe \nimported \nthe State have undergone \ncertification of batch release either in the \nUnion, as provided for in Article 13, paragraph \n3, point (a) of the Directive or in parts of the \nUnited Kingdom other than Northern Ireland \nin compliance with the requirements set out in \nArticle 13, paragraph 3, point (b) of the \nDirective, and \nthe investigational medicinal products are only \nmade available to subjects in the State; and” \n\n(II) \n\n(b) by substituting for subparagraph 2(d) the following: \n\n“(d) the production batch of investigational medicinal product \nof which the product is a part has been checked and \ncertified by a qualified person pursuant to Regulation 40 \nwho operates in – \n(i) \nan EEA State, \n(ii) Northern Ireland, or \n(iii) until 31 December 2024, parts of the United \nKingdom other than Northern Ireland and the \ninvestigational medicinal product is only made \navailable to subjects in the State.”", "text_norm": "4 regulation 4(1) amended - (a) substituting definition directive following directive mean directive 2001 20 ec1 european parliament council 4 april 2001 approximation law regulation administrative provision member state relating implementation good clinical practice conduct clinical trial medicinal product human use (as amended) (b) substituting definition directive 2001 83 ec following directive 2001 83 ec mean directive 2001 83 ec european parliament council community code relating medicinal product human use3 (as amended) (c) substituting definition export following export mean export third country northern ireland state whether land sea air (d) substituting definition import following import mean import state third country northern ireland whether land sea air  1 oj no l 118 20.4.2022 p.4 1 oj no l 121 01.05.2001 p.34 3 oj no l 311 28.11.2001 p.67 notice making statutory instrument published iris oifigiuil 23rd august 2022 5 regulation 11 principal regulation hereby amended - (a) substituting subparagraph 2(c) following 417 3 (c) case investigational medicinal product - (i) (ii) imported third country product imported person holding manufacturing authorisation relating importation product imported part united kingdom northern ireland 31 december 2024 board may allow product imported absence manufacturing authorisation relating importation product following receipt request sponsor provided following condition fulfilled - (i) investigational medicinal product imported state undergone certification batch release either union provided article 13 paragraph 3 point (a) directive part united kingdom northern ireland compliance requirement set article 13 paragraph 3 point (b) directive investigational medicinal product made available subject state (ii) (b) substituting subparagraph 2(d) following (d) production batch investigational medicinal product product part checked certified qualified person pursuant regulation 40 operates - (i) eea state (ii) northern ireland (iii) 31 december 2024 part united kingdom northern ireland investigational medicinal product made available subject state", "start_char": 1091, "end_char": 4133, "source_path": "downloads\\2022\\2022_0416.pdf", "extraction_method": "pdfminer", "checksum": "sha256:3fb589c64e11faf5663ec09f19a158402de82e69872a1dc3fba31872e00a5d0a", "cross_refs": []}
{"doc_id": "si-2022-0417-reg-6", "parent_doc_id": "si-2022-0417", "section_id": "reg-6", "section_label": "Regulation 6.", "si_number": "S.I. No. 417 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "6. The Principal Regulations are amended by inserting after Part 9 the", "text_raw": "6. The Principal Regulations are amended by inserting after Part 9 the \n\nfollowing Part: \n\n“PART 10 \n\nDEROGATIONS", "text_norm": "6 principal regulation amended inserting part 9 following part part 10 derogation", "start_char": 4133, "end_char": 4249, "source_path": "downloads\\2022\\2022_0416.pdf", "extraction_method": "pdfminer", "checksum": "sha256:3fb589c64e11faf5663ec09f19a158402de82e69872a1dc3fba31872e00a5d0a", "cross_refs": []}
{"doc_id": "si-2022-0417-reg-53", "parent_doc_id": "si-2022-0417", "section_id": "reg-53", "section_label": "Regulation 53.", "si_number": "S.I. No. 417 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "53. (1) By 20 May 2022, the Board shall establish, notify to the", "text_raw": "53. (1) By 20 May 2022, the Board shall establish, notify to the \nCommission and publish on its website a list of medicinal products to which it \nhas applied or intends to apply the derogations as set out in Regulations \n11(2)(c) and 11(2)(d) of these Regulations. \n\n \n \n \n \n\f4 [417] \n\n(2) The Board shall ensure that the list referred to in paragraph (1) is \n\nupdated at least on a six-monthly basis. \n\n(3) Any sponsor who intends to avail of the derogations set out in \nRegulations 11(2)(c) and 11(2)(d) of these Regulations for an investigational \nmedicinal product shall notify the Board and ensure that the relevant \ninvestigational medicinal product is included on the list referred to in \nparagraph (1) before the relevant investigational medicinal product is supplied \nfor use in the clinical trial.” \n\nGIVEN under the Official Seal of the Minister for Health, \n\n18 August, 2022. \n\nMUIRIS O'CONNOR, \n\nA person authorised under section 15 of the Ministers and \nSecretaries Act 1924 to authenticate the seal of the \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n\f[417] 5", "text_norm": "53 (1) 20 may 2022 board shall establish notify commission publish website list medicinal product applied intends apply derogation set regulation 11(2)(c) 11(2)(d) regulation 4 417 (2) board shall ensure list referred paragraph (1) updated least six-monthly basis (3) sponsor intends avail derogation set regulation 11(2)(c) 11(2)(d) regulation investigational medicinal product shall notify board ensure relevant investigational medicinal product included list referred paragraph (1) relevant investigational medicinal product supplied use clinical trial given official seal minister health 18 august 2022 muiris connor person authorised section 15 minister secretary act 1924 authenticate seal minister health 417 5", "start_char": 4249, "end_char": 5325, "source_path": "downloads\\2022\\2022_0416.pdf", "extraction_method": "pdfminer", "checksum": "sha256:3fb589c64e11faf5663ec09f19a158402de82e69872a1dc3fba31872e00a5d0a", "cross_refs": []}
{"doc_id": "si-2022-0417-explanatory-note", "parent_doc_id": "si-2022-0417", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 417 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "(This note is not part of the instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the instrument and does not purport to be a legal \ninterpretation) \n\nThe main purpose of these Regulations is to implement Articles 1 and 2(11) of \nDirective (EU) 2022/642 of the European Parliament and of the Council of 12 \nApril 2022, which amend Directive 2001/20/EC and Directive 2001/83/EC as \nregards derogations from certain obligations concerning certain medicinal \nproducts for human use. \n\n \n \n \n \n \n\f6 [417] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(DH-439) 75. 8/22. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation) main purpose regulation implement article 1 2(11) directive (eu) 2022 642 european parliament council 12 april 2022 amend directive 2001 20 ec directive 2001 83 ec regard derogation certain obligation concerning certain medicinal product human use 6 417 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.00 (dh-439) 75 8 22 propylon", "start_char": 5325, "end_char": 6274, "source_path": "downloads\\2022\\2022_0416.pdf", "extraction_method": "pdfminer", "checksum": "sha256:3fb589c64e11faf5663ec09f19a158402de82e69872a1dc3fba31872e00a5d0a", "cross_refs": []}
